Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: A simulation analysis

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 255-264

  Gaebler, Julia A ^a   Soto Campos, Gerardo ^b   Alperin, Peter ^b   Cohen, Marc ^b   Blickensderfer, Amy ^a   Wintle, Matthew ^a   Maggs, David ^a   Hoogwerf, Byron ^c   Han, Jenny ^a   Pencek, Richard ^a   Peskin, Barbara ^b  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b Archimedes Inc   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Cardiovascular risk; Diabetes; Exenatide; Insulin; Modeling; Pioglitazone

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE; VENOM;

ADVERSE OUTCOME; ARTICLE; COST BENEFIT ANALYSIS; DIABETIC MICROANGIOPATHY; DRUG COST; DRUG EFFECT; DRUG SAFETY; HEMOGLOBIN BLOOD LEVEL; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; QUALITY ADJUSTED LIFE YEAR; SIMULATION; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; AGED; BLOOD; COMPARATIVE STUDY; COMPUTER SIMULATION; DIABETIC ANGIOPATHY; DRUG ADMINISTRATION; ECONOMICS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NUTRITION; PATIENT COMPLIANCE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; UNITED STATES;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, ECONOMIC; NUTRITION SURVEYS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PEPTIDES; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENOMS;

EID: 84864705670     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S28744     Document Type: Article

References (30)

1. Center for Disease Control and Prevention. Diabetes data and trends: national surveillance data - number (in millions) of civilian, non-institutionalized adults with diagnosed diabetes, United States,1980-2009. c2011 [updated March 30, 2011]. Available from: http://www.cdc.gov/diabetes/statistics/prev/national/figadults.htm. Accessed November 13, 2011.
2. Center for Disease Control and Prevention. Diabetes data and trends: national surveillance data-diabetes complications. c2011 [updated June 16, 2011]. Available from: http://www.cdc.gov/diabetes/statistics/complications_national.htm. Accessed November 13, 2011.
3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. c2011 [Updated November 8, 2011]. Available from: http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed November 13, 2011.
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
5. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
6. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
7. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-126.
8. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care. 2011;34 Suppl 1:S11-S61.
9. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J Biol Chem. 1992;267:7402-7405.
10. BYETTA® (exenatide) injection. Full prescribing information. c2010 [Revised September 2010; Amylin Pharmaceuticals Inc, San Diego, CA] Available from: http://pi.lilly.com/us/byetta-pi.pdf. Accessed August 20, 2011.
11. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470-512.
12. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234-2243.
13. Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301-1310.
14. Taylor K, Gurney K, Han J, Pencek R, Walsh B, Trautmann M. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord. 2011;11:9.
15. Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011;28:705-714.
16. Eddy D, Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care. 2003;26:3102-3110.
17. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and costeffectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251-264.
18. Alperin P, Soto-Campos G, Peskin B, et al. Understanding the effect of glycemic control on macrovascular outcomes in patients with diabetes using the Archimedes Model [abstract]. Diabetes. 2010;59:Abstract 879-P.
19. Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010;375:1365-1374.
20. Brown JB, Nichols GA, Glauber HS, Bakst A. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther. 1999;21:1045-1057.
21. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control. Diabetes Care. 2005;28:78-83.
22. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES). c2011. Available from: http://www.cdc.gov/nchs/nhanes.htm. Accessed June 23, 2011.
23. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost- Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
24. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26:410-420.
25. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492-1495.
26. Cleveland WS, Grosse E, Shyu MJ. Local regression models. In: Chambers JM, Hastie T, editors. Statistical Models in S. New York, NY: Chapman and Hall; 1992:309-376.
27. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
28. Skyler JS, Bergenstal R, Bonow RO, et al; for American Diabetes Association, American College of Cardiology Foundation, and American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientif ic statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187-192.
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
30. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.